Unfractionated heparin (UFH) and low-molecularweight heparin (LMWH) are widely used anticoagulants for surgical and interventional use. Currently, the anticoagulant and bleeding effects of heparin are neutralized by protamine sulfate. There are several problems associated with the use of protamine sulfate, including allergic reactions, cardiovascular effects, heparin rebound, and incomplete neutralization of LMWHs. The objective of this investigation is to characterize the effectiveness of a novel salicylamidederived heparin antagonist, PMX 60056, in neutralizing the antithrombotic and bleeding effects of UFH and LMWHs. Animals were first anticoagulated using an intravenous injection of UFH or LMWH followed by protamine sulfate or PMX 60056. Established animal models of hemorrhage (rat-tail transection) and thrombosis (jugular vein clamping) were then performed. Blood samples were collected for ex vivo analysis using activated partial thromboplastin time (aPTT), anti-Xa, and anti-IIa assays. We demonstrate that PMX 60056 neutralized the antithrombotic, anticoagulant, and bleeding effects of heparins as effectively as protamine sulfate and may be slightly more efficacious against LMWHs. These results suggest that PMX 60056 may provide an improved approach for the neutralization of UFH and LMWHs.
H eparin is a mixture of glycosaminoglycan chains, ranging in molecular weight from approximately 3000 to 30 000 Da, that produces anticoagulant activity. 1 Most of heparin's anticoagulant activity is a result of its ability to bind to the plasmatic protein antithrombin (AT) and catalyze its inhibition of coagulation proteases. Other anticoagulant properties of heparin are related to its high degree of negative charge. Heparin chains of varying molecular weight exhibit varying pharmacologic effects. [2] [3] [4] For example, it is well appreciated that there is a minimal heparin chain length required to promote thrombin inhibition. 5 In addition, pharmacokinetic behavior is influenced by chain length, with shorter heparin chains exhibiting a higher bioavailability and slower clearance than larger chains. 1 Such differences in pharmacokinetic and pharmacologic effects have led to the pharmaceutical development and clinical acceptance of the low-molecular-weight heparins (LMWHs). 6 The LMWHs have been shown in a number of clinical trials to be safe and effective in the prevention and treatment of venous thrombosis. 7 More recently, the effectiveness of higher doses of LMWHs for the treatment of patients with pulmonary embolism or acute coronary syndrome has been established. 8, 9 An increased risk of hemorrhage is one of the important complications associated with the use of heparins. One means of treating heparin-induced hemorrhage or preventing excessive postsurgical bleeding is pharmacologic antagonism. 1, 10, 11 Unfractionated heparin (UFH) is typically neutralized by the administration of protamine sulfate. Protamine sulfate binds heparin in a chargedependent fashion and prevents it from interacting with plasmatic cofactors. Although widely used, the pharmacologic profile of protamine sulfate raises several safety and efficacy concerns. 12, 13 In addition to adverse clinical events such as hypotension, bradycardia, and anaphylaxis, re-emergence of anticoagulant activity after adequate dosing of protamine sulfate can result. This phenomenon, known as heparin rebound, is thought to occur due to the differential kinetics of heparin and protamine sulfate in the circulation. Additionally, protamine sulfate has been shown to be less effective at neutralizing LMWHs, perhaps due to molecular and structural differences between protamine and LMWHs. 1, 10, 14 Considering the increasing use of LMWHs, it is desirable to have an agent that is capable of more completely neutralizing LMWHs.
Until now, alternate approaches for the neutralization of heparins have met with little success. Polybrene (hexadimethrine bromide) binds to heparin in a charge-dependent fashion and neutralizes its anticoagulant effects. 15, 16 Although a potent inhibitor of heparin, rapid administration of polybrene can be associated with systemic hypotension, decreases in systemic vascular resistance, and increases in pulmonary artery pressure. Issues with renal toxicity 17, 18 have limited the clinical use of polybrene. Platelet factor 4 (PF4) is a heparin-binding protein found in platelet a-granules. Recombinant PF4 has been administered safely to patients to reverse heparin after cardiac catheterization 19 and reverses heparin-induced anticoagulation ex vivo following cardiopulmonary bypass. 20 Unfortunately, heparin-PF4 complexes are antigenic and can lead to the development of heparin-induced thrombocytopenia. 21 Heparinase-I is an enzyme isolated from Flavobacterium heparinum, which degrades heparin. 22 While effective when supplemented in vitro and ex vivo, 23 administration of heparinase to heparinized patients was associated with an unacceptable safety profile. 24 The development of novel salicylamide derivatives such as PMX 60056 may represent an improved pharmacological approach to neutralize heparins. Previous work has demonstrated its effectiveness following in vitro supplementation. 25 In this study, we demonstrate the ability of PMX 60056 to neutralize the hemorrhagic and antithrombotic effects of heparin and a LMWH, enoxaparin, using standardized animal models.
Materials
Unfractionated heparin (UFH) and the LMWH, enoxaparin, were obtained from Sanofi-Aventis (Paris, France). Protamine sulfate, obtained from Institut Choay (Paris, France), had an approximate molecular weight of 6000 Da. PMX 60056 was obtained from Polymedix, Inc (Radnor, Pennsylvania) and had a molecular weight of 940 Da. PMX60056, tetra-[5-(L)-lysyl-amino-O-methylsalicylamide], is a fully synthetic foldamer comprised of 4 repeating lysyl-salicylamide units. It was designed to mimic the binding surface of antithrombin that interacts with the pentasaccharide of heparin. Unfractionated heparin, LMWH, protamine, and PMX 60056 were all obtained as powders, stored at room temperature, and dissolved in sterile saline to make working solutions. Male Sprague-Dawley rats weighing between 250 and 274 g were obtained from Harlan Laboratories (Indianapolis, Indiana).
Methods
A rat-tail bleeding time model was used to compare the ability of protamine sulfate and PMX 60056 to reverse the hemorrhagic effects of UFH and LMWH following intravenous administration. 26, 27 A rat jugular vein clamping model was used to assess the ability of PMX 60056 to neutralize UFH-and LMWH-induced antithrombotic activity following intravenous administration. 28 Animal protocols were reviewed and approved by the Loyola University Medical Center Institutional Animal Care and Use Committee (IACUC). All staff working with animal models were trained and supervised per protocol. Citrated rat pool plasma samples were supplemented with graded amounts of UFH and LMWH and the neutralization profile was measured using anticoagulant and antiprotease assays to generate standard curves.
In Vivo
Male, Sprague-Dawley rats (250-275 g) were anesthetized (90 mg/kg ketamine þ 10 mg/kg xylazine, intramuscular bolus) and allowed to rest for 10 minutes until the heart rate and breathing stabilized. A single intravenous (IV) bolus of UFH or LMWH (2.0 mg/kg) was injected into the tail vein. Five minutes later, individual groups of rats (n ¼ 5 per anticoagulant/antagonist combination) were administered 1 of 3 intravenous doses (0.5 mg/kg, 1.0 mg/kg, or 2.0 mg/kg) of protamine sulfate or PMX 60056. Control groups were given 2 injections of saline or an injection of LMWH or UFH followed by an injection of saline.
Rat tail transection model. Five minutes after the injection of the neutralizing agent (or saline), the distal 2 mm of the rat tail was transected using a disposable scalpel blade. Excess blood was blotted with filter paper every 30 seconds until clot formation to measure the time to bleeding cessation. Jugular vein clamping model. Upon completion of the rat-tail bleeding procedure, the right jugular vein was surgically isolated, covered lightly with salinesoaked gauze, and allowed to recover for 10 minutes. Baseline measure of blood flow was taken with a Doppler probe (Model 806-CB Directional Doppler; Parks Medical Electronics Inc Aloha, Oregon). The jugular vein was then clamped for 1 minute using a mosquito forceps and allowed to recover for 5 minutes before the next flow measurement was taken. Clamping cycles continued until Doppler flow measurements indicated complete occlusion of the vein. Cessation of blood flow was supported by visual examination of the vein.
Ex Vivo
Blood samples were collected via cardiac puncture prior to euthanasia. All blood samples were anticoagulated using 3.2% sodium citrate (9 parts blood:1 part citrate) and were immediately centrifuged. Activated partial thromboplastin time (aPTT) was measured on the freshly isolated plasma. Remaining plasma was frozen at À70 C and subsequently batch analyzed for anti-IIa and anti-Xa activity.
Anticoagulant activity assays. Anticoagulant activity in plasma supplemented with heparin (or LMWH) and protamine sulfate (or PMX 60056) and blood samples collected from treated rats was measured in terms of prolongation of the aPTT (Platelin L, bioMérieux, Durham, North Carolina) determined using manually operated fibrometers (BBL, Cockeysville, Maryland) Antiprotease assays. Human factor-Xa and human thrombin were obtained from Enzyme Research Laboratories (South Bend, Indiana). Amidolytic substrates (Spectrozyme Xa and Spectrozyme TH) were obtained from American Diagnostica (Stamford, Connecticut). Anti-factor-Xa and antifactor-IIa assays were performed on an ACL 300 Plus fast kinetics coagulation analyzer (Beckman-Coulter, Hialeah, Florida) Optical density values were converted into percentage factor-Xa or -IIa inhibition by using the following formula:
All antiprotease results were expressed as percentage inhibition.
Statistical Analysis
For the bleeding and antithrombotic studies, data represent mean + 1 standard deviation. In vitro test results such as antiprotease activities are presented as mean + SEM. Paired t test was performed to determine the statistical significance of findings (P < .05).
Results
Normal human plasma, anticoagulated with either 10 mg/mL heparin or 10 mg/mL enoxaparin, was supplemented with either vehicle or increasing concentrations of protamine or PMX 60056. Anti-Xa and anti-IIa activities of the plasma samples were determined by amidolytic assay. In heparinized plasma, PMX 60056 was more potent on a gravimetric basis than protamine at neutralizing both anti-Xa and anti-IIa activities ( Figure 1B and D) . Additionally, unlike protamine, PMX 60056 was able to completely neutralize heparin at an approximate 2:1 gravimetric ratio. The amount of residual anti-IIa and anti-Xa activity was significantly less with PMX 60056 at a concentration of 50 mg/mL. In plasma anticoagulated with enoxaparin, PMX 60056 produced a concentration-dependent neutralization of anti-Xa activity whereas protamine was observed to have no effect ( Figure 1C ). The amount of anti-Xa activity remaining after supplementation of the neutralizing agent was significantly less with PMX 60056 at concentrations above 25 mg/mL.
We then utilized standardized animal models to compare the effectiveness of PMX 60056 and protamine at neutralizing the hemorrhagic and antithrombotic actions of heparin and enoxaparin. At a dose of 2.0 mg/kg IV, UFH produced a marked prolongation in the tail transection time in comparison to the saline control (29.1 + 5.1 minutes vs 7.3 + 1.4 minutes; P < .001; Figure 2 ). Administration of both protamine sulfate and PMX 60056 at doses ranging from 0.5 mg/kg to 2.0 mg/kg produced a dosedependent decrease in the tail transection time. With 2 mg/kg of either antagonist the tail transection time was reverted to near baseline values.
At a dose of 2.0 mg/kg IV, enoxaparin produced a sizeable prolongation in the tail transection time in comparison to the saline control (16.7 + 3.6 minutes vs 7.3 + 1.4 minutes; P < .001; Figure 3 ). The prolongation was notably smaller than observed in heparintreated rats. At doses ranging from 0.5 mg/kg to 2.0 mg/kg, both protamine sulfate and PMX 60056 produced a dose-dependent decrease in the tail transection time. However, at the 0.5 mg/kg dose, the Figure 1 . Normal human plasma, anticoagulated with heparin or enoxaparin at a concentration of 10 mg/mL, was supplemented with protamine or PMX 60056 at concentrations ranging from 12.5 to 50 mg/mL. Anti-Xa and anti-IIa activities were determined using amidolytic assays. All results represent the mean + SD of 3 measurements. decrease in the tail transection time following administration of PMX 60056 was less than following administration of protamine. Upon completion of the rat-tail bleeding model, residual antithrombotic activity was measured using the jugular vein clamping model. At a 2.0 mg/kg dose, UFH produced a strong antithrombotic effect in comparison to the saline-treated group (7.2 + 1.1 clampings vs 3.4 + 0.5 clampings; Figure 4 ). Both antagonists produced a comparable and dosedependent decrease in the antithrombotic effects of UFH. A strong residual antithrombotic effect was also observed in enoxaparin-treated animals compared to the saline-treated group (7.0 + 0.6 clampings vs 3.4 + 0.5 clampings; Figure 5 ). Both protamine and PMX 60056 produced a comparable neutralization of the antithrombotic effects of enoxaparin in a dose-independent manner.
Blood samples were collected from treated rats for the ex-vivo analyses of anticoagulant activity. Protamine sulfate and PMX 60056 produced varying degrees of neutralization of the heparin-induced prolongation of the aPTT ( Figure 6A ). Although wide scatter in the data is observed, neutralization of the aPTT prolongation appeared stronger with PMX 60056 than that observed with protamine sulfate.
Enoxaparin treatment produced a prolongation of the aPTT ( Figure 6B ). Both protamine sulfate and PMX 60056 produced comparable, doseindependent neutralization of anticoagulant activity.
The blood samples were also analyzed using amidolytic anti-Xa and anti-IIa assays. Neutralization of anti-factor Xa activity in rats anticoagulated with heparin was higher with PMX 60056 at doses of 1.0 and 2.0, respectively ( Figure 7A) . A wide scatter of the anti-IIa data was observed. Overall, a dose-dependent neutralization was seen with both agents ( Figure 7B) .
A dose-dependent neutralization of anti-factor-Xa activity in rats anticoagulated with enoxaparin was noted with both agents ( Figure 8A) . A dosedependent response was noted for protamine sulfate ( Figure 8B ). Due to the limited amount of sample only the results of the 0.5 mg/kg of the PMX 60056-treated group are depicted in this graph.
Discussion
Protamine sulfate has remained the sole antagonist for the neutralization of anticoagulant actions of heparin. 1, 6 The use of protamine sulfate is associated with several adverse side effects including allergic effects, hemodynamic changes, and bradycardia. 12, 13 Although protamine sulfate is useful for the neutralization of UFH, it has a limited value for the neutralization of LMWHs. Thus, there is need for improved antidotes for UFH and LMWHs. 1, 10, 14 The development of salicylamide derivatives such as PMX 60056 provides a new approach for the neutralization of both UFH and LMWHs. Since the main adverse effect of heparin is hemorrhage, a variety of animal models of bleeding have been used to investigate the hemorrhagic effects of these drugs and their neutralization. [26] [27] [28] Equigravimetric dosages of protamine and PMX 60056 effectively neutralized the bleeding effects of UFH following intravenous administration. Although the molecular weight of PMX 60056 is considerably lower than that of protamine, there was no difference in their neutralization profiles.
In the current studies, the relative efficacies of protamine sulfate and PMX 60056 were determined in a rat model following single intravenous bolus doses ranging from 0.5 to 2.0 mg/kg. Lower bleeding effects were observed with LMWH compared to UFH at the 2.0 mg/kg dose, and both agents effectively neutralized the bleeding effects of LMWH in this model. As LMWHs are typically administered in this fashion, additional studies are warranted to access the efficacy of PMX 60056 in neutralizing LMWHs administered subcutaneously. The data reported in this study demonstrates clearly that PMX 60056 is equally effective in neutralizing the bleeding effects of both UFH and enoxaparin when administered intravenously.
The antithrombotic effects of heparin and related drugs have been extensively studied in various animal models. 26 In this study, a rat jugular vein clamping model was used to determine the relative neutralizing effects of PMX 60056 and protamine sulfate. The antithrombotic effects of both UFH and enoxaparin were neutralized by protamine and PMX 60056 over a dose range of 0.5 to 2.0 mg/kg. While there was no difference in the antithrombotic effects of UFH and enoxaparin, both protamine sulfate and PMX 60056 produced a dose-dependent neutralization of the effect of UFH. Interestingly, however, the neutralization profile of enoxaparin was doseindependent with regard to either neutralizing agent, which perhaps may be attributed to the lowmolecular-weight profile of enoxaparin. Nonetheless, this is suggestive of differential mechanisms for the mediation of the antithrombotic and bleeding effects in these models. The pharmacologic effects of heparins are mediated by several mechanisms involving the interaction of these drugs with antithrombin and heparin cofactor II. In addition, both drugs are capable of displacing Tissue factor pathway inhibitor (TFPI) from the vascular lining. 29 Several laboratory tests are commonly used to measure the pharmacodynamic effects of heparins in blood plasma. In these studies, a global clot-based assay (aPTT) and amidolytic methods (anti-Xa and anti-IIa) were used to assess the circulating levels of anticoagulant and antiprotease activities of heparins.
Heparin at an intravenous dose of 2.0 mg/kg produced a marked prolongation of the clotting time in comparison to saline control. Although both protamine sulfate and PMX 60056 neutralized UFH's hemorrhagic and antithrombotic effects in a doseindependent manner, PMX 60056 produced a more effective neutralization than protamine sulfate in these ex vivo assays.
As expected, the prolongation of the aPTT with LMWH was weaker than with UFH. Both neutralization agents produced a partial reduction in the prolongation of the aPTT in a dose-independent fashion. The differential neutralization of LMWH in comparison to heparin may be related to lower molecular weight of enoxaparin. In the amidolytic Activated partial thromboplastin time (aPTT) was measured on freshly isolated plasma obtained from blood samples collected from rats anticoagulated with heparin or enoxaparin and subsequently treated with protamine or PMX 60056. Heparin produced a larger prolongation of aPTT than enoxaparin. PMX 60056 appeared to more effectively reverse the heparin-induced prolongation of clotting time. anti-Xa and anti-IIa assays, large variations within animal groups were noted. One possible cause of these variations is the timing of blood sample collection. All blood samples were collected on completion of the jugular vein clamping model. Thus, interanimal variations in hemorrhagic or antithrombotic activity would impact the time from heparin antagonist administration until blood collection. While both protamine sulfate and PMX 60056 produced a concentration-dependent neutralization of anti-Xa and anti-IIa activities in the rats treated with UFH; the neutralization effects were not complete. In contrast, in the case of enoxaparin, a near-complete inhibition of anti-Xa and anti-IIa activities was noted at 1.0 and 2.0 mg/kg doses. At the lower dosage 0.5 mg/kg of antagonist, only a partial neutralization was observed.
The differences in the neutralization profile of protamine sulfate and PMX 60056 as measured by the anti-Xa/IIa methods may be related to the molecular composition of UFH and LMWH. The prevalence of high-molecular weight components responsible for anti-IIa effects in LMWH is much lower than that in UFH. Therefore, both PMX 60056 and protamine sulfate produced an almost complete neutralization of anti-IIa effects in enoxaparin in comparison to those observed with heparin.
One of the limitations of this study is that both UFH and LMWH were administered at a fixed dosage of 2.0 mg/kg IV. The relative anticoagulant effects of UFH were disproportionately higher in comparison to LMWH. Moreover, there are significant differences in the biologic half-life of these two agents even after IV administration. 1, 30 Regardless of these limitations, our study demonstrates that the novel salicylamide derivative, PMX 60056, is equally effective as standard protamine sulfate in neutralizing the bleeding and antithrombotic effects of UFH and LMWH. Similar studies to demonstrate the dose-dependent effects of both neutralizing agents while using heparins at varied equigravimetric doses and biologic potencybased dosing (USP U/kg) would provide additional information on the dose-dependence of antithrombotic and hemorrhagic effects.
PMX 60056 has the potential to provide a useful substitute for the neutralization of heparin and LMWHs. Current studies have also demonstrated that PMX 60056 is a relatively effective antagonist for LMWHs in comparison to UFH. Moreover, due to its low-molecular-weight (940 Da), PMX 60056 may be absorbed following subcutaneous administration. Thus, additional preclinical and clinical investigation is warranted to further probe the potential of this salicylamide derivative in the neutralization of heparin. 
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